Publications by authors named "Roland Repp"

Claim this Profile
M
Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.
Johannes Lübke, Nicole Naumann, Timo Brand, Laurenz Steiner, Roland Repp

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, Sven Zukunft, Barbora Weinbergerová, Roland Repp

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.
Leo Ruhnke, Marius Bill, Sven Zukunft, Jan-Niklas Eckardt, Silvia Schäfer, Roland Repp

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Hematopoietic Stem Cell Transplantation From a CD36+ Donor in an Immunized Patient With Type I Hereditary CD36 Deficiency.
Nicolas Spath, Philipp Nakov, Sven-Ole Schuster, Daniel Kownatzki-Danger, Dagmar Steppat, Roland Repp

Transplantation· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.
Julia Winkler, Hannes Tittlbach, Andrea Schneider, Ingrid Vasova, Julian Strobel, Roland Repp

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease.
Lennart Philippen, Natalie Schub, Andreas Günther, Gunnar Cario, Martin Schrappe, Roland Repp

Bone Marrow Transplant· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Christoph Röllig, Hubert Serve, Richard Noppeney, Maher Hanoun, Utz Krug, Roland Repp

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment.
Gordon F Heidkamp, Jil Sander, Christian H K Lehmann, Lukas Heger, Nathalie Eissing, Roland Repp

Sci Immunol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller-Tidow, Roland Repp

Lancet Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
Christian Kellner, Andreas Günther, Andreas Humpe, Roland Repp, Katja Klausz

Oncoimmunology· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity.
Anja Lux, Michaela Seeling, Anne Baerenwaldt, Birgit Lehmann, Inessa Schwab, Roland Repp

Cell Rep· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Anna Czajczynska, Andreas Günther, Roland Repp, Andreas Humpe, Natalie Schub

Biol Blood Marrow Transplant· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
Sahar Mohseni Nodehi, Roland Repp, Christian Kellner, Joachim Bräutigam, Matthias Staudinger

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Christian Kellner, Tina Maurer, Daniela Hallack, Roland Repp, Jan G J van de Winkel

J Immunol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Roland Repp, Christian Kellner, Anja Muskulus, Matthias Staudinger, Sahar Mohseni Nodehi

J Immunol Methods· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Tapani Ruutu, Liisa Volin, Dietrich W Beelen, Rudolf Trenschel, Juergen Finke, Roland Repp

Haematologica· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies.
Holly M Horton, Matthew J Bernett, Matthias Peipp, Erik Pong, Sher Karki, Roland Repp

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Yvonne Guettinger, Karin Barbin, Matthias Peipp, Joerg Bruenke, Michael Dechant, Roland Repp

J Immunol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Massive swelling of the cervical region: an uncommon manifestation of B cell chronic lymphocytic leukemia.
Stephan T Becker, Jörg Wiltfang, Wolfram Klapper, Roland Repp, Nektarios Sinis

Oral Maxillofac Surg· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Holly M Horton, Matthew J Bernett, Erik Pong, Matthias Peipp, Sher Karki, Roland Repp

Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Matthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, Wim W K Bleeker, Michael Dechant, Roland Repp

Blood· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cup-like acute myeloid leukemia: new disease or artificial phenomenon?
Frank P Kroschinsky, Ulrike Schäkel, Rainer Fischer, Brigitte Mohr, Uta Oelschlaegel, Roland Repp

Haematologica· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity.
Heike Horner, Carola Frank, Claudia Dechant, Roland Repp, Martin Glennie

J Immunol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, Hans-Peter Böck, Roland Repp

Blood· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.
Juergen Rech, Roland Repp, Dorit Rech, Bernhard Stockmeyer, Michael Dechant

Leuk Lymphoma· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis